CompletedPhase 3

Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm

China332 participantsStarted 2005-12

Plain-language summary

To compare the effectiveness and safety of Dysport® with the domestic Botulinum Toxin Type A (manufactured by Lanzhou Biologic Product Institute, P.R. China) for the treatment of hemifacial spasm.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient suffering from hemifacial spasm with at least 6 months duration (prior to visit 1) * Cohen scale ≥ to grade II Exclusion Criteria: * Botulinum toxin type A treatment history within last 16 weeks prior to visit 1 * Hemifacial spasm secondary to facial palsy * Previous alcohol or phenol injections or surgical therapy of the facial muscles * Requirement for botulinum toxin injection to site(s) of the body other than in this study

What they're measuring

Percentage of responders (defined as Cohen scale improvement ≥ to 2 levels)

Timeframe: At the end of week 4

Trial details

NCT IDNCT00276315

SponsorIpsen

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Hemifacial Spasm trials